Health & Medicine
-
COVID-19: 100% Survival Rate Therapy of Israeli-based Pluristem Tested on US patient
The Israeli-based Pluristem Therapeutics Inc. announced on April 13 that it has treated its first American patient suffering from COVID-19 complications in the United States under the U.S. Food and Drug Administration (FDA) Single Patient Expanded Access Program or compassionate program.
Latest Research Articles
-
African-Americans Most Likely to Get COVID-19: Here Are Reasons Why
-
Quarantine Binge Drinking May End Badly
-
Scientists: Dogs May Detect the Coronavirus in Humans
Spider Venom Can be a Pain Killer Sans the Side Effects
-
Remdesivir, Highly Effective in Preventing Replication of Coronavirus
-
Understanding the Health Risks of Working from Home
-
Hair Loss More Evident in Asian Men, Previously with the Lowest Incidence
-
Essential Food Supplements for Women
Explainers on Some Myths You've Heard About Gynecomastia
-
Summer Heat May Not Diminish Coronavirus Strength
-
Families Vying for Access to COVID-19 Convalescent Plasma Therapy Frantic
-
Prepare for the Worst: Have Your Survival Kit Ready
MOST POPULAR
-
Weak Spot in Earth's Magnetic Field Raises Concerns for Humanity's Future
-
Spectacular Northern Lights Show Possible in 10 States as Geomagnetic Storm Approaches
-
Earth's Magnetic North Pole Shifts Toward Russia, Scientists Update Its Location
-
Undersea Volcano Off Oregon Coast Could Erupt in 2025 After Scientists Notice 'Swelling'
-
Mount Rainier's Volcanic Activity Closely Watched by Scientists
